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The onset and progression of numerous protein misfolding diseases are associated with the
presence of oligomers formed during the aberrant aggregation of several different proteins,
including amyloid-β (Aβ) in Alzheimer’s disease and α-synuclein (αS) in Parkinson’s disease.
These small, soluble aggregates are currently major targets for drug discovery. In this study, we
show that trodusquemine, a naturally-occurring aminosterol, markedly reduces the cytotoxicity
of αS, Aβ and HypF-N oligomers to human neuroblastoma cells by displacing the oligomers
from cell membranes in the absence of any substantial morphological and structural changes to
the oligomers. These results indicate that the reduced toxicity results from a mechanism that is
common to oligomers from different proteins, shed light on the origin of the toxicity of the most
deleterious species associated with protein aggregation and suggest that aminosterols have the
therapeutically-relevant potential to protect cells from the oligomer-induced cytotoxicity
associated with numerous protein misfolding diseases.
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The deposition of a range of peptides and proteins aspathological aggregates plays a central role in the etiology ofover fifty human disorders, including the amyloid-β protein
(Aβ) in Alzheimer’s disease and α-synuclein (αS) in Parkinson’s
disease1–3. During the aggregation reaction, monomeric proteins
that are normally soluble misfold, self-associate and ultimately
form amyloid fibrils with a characteristic cross-β structure, through
a mechanism that has been shown to be common to a wide range
of proteins1–3. Increasing evidence suggests that the small soluble
oligomers formed during the aggregation process of such amyloi-
dogenic proteins are highly likely to play an important role in the
onset and progression of diseases3–6. Oligomers are therefore
major targets for drug discovery against protein misfolding dis-
eases. Different mechanisms through which the oligomers exert
their toxicity have been reported, for example by impairing and
sequestering functional forms of proteins7, compromising the
integrity of lipid membranes8,9, interacting with membrane pro-
teins, particularly calcium channels10, and stimulating the immune
response11.
The application of a highly sensitive kinetic assay to characterize
the aggregation behavior of the 42-residue form of the amyloid-β
protein (Aβ42)12–14 has suggested the possibility of reducing the
toxicity inherent to protein aggregation by targeting the generation
of oligomers15. This methodology has enabled the detailed eva-
luation of compounds, including molecular chaperones, antibodies,
and small molecules, for their abilities to inhibit the aggregation
process of Aβ42 in a specific manner so that the overall con-
centration of oligomers produced during the process is reduced.
Such compounds have the potential to serve in a therapeutic
capacity by targeting specifically the microscopic steps of Aβ42 that
are responsible for oligomer production and proliferation15–19.
Similar strategies have been employed to identify species that
inhibit oligomer formation by αS, in particular by targeting the
microscopic step of fibril amplification20–22.
We have previously reported that the small molecule tro-
dusquemine, an aminosterol first discovered in dogfish sharks
and initially investigated for its therapeutic potential against
bacterial infection, obesity, cancer, and anxiety disorders23–26,
and as a stimulant of tissue regeneration27, acts as a potent
inhibitor of αS aggregation by reducing the rates associated with
the lipid-induced nucleation and fibril amplification steps in the
aggregation process20. In a surprising contrast, we also found that
trodusquemine enhances the aggregation of Aβ42 by increasing
the rate of monomer-dependent secondary nucleation and, to a
lower extent, fibril elongation, while maintaining the rate of
primary nucleation almost unaffected28. Despite the distinct
mechanisms of the aggregation of αS and Aβ42 and the differing
effects of trodusquemine on the underlying processes, however,
these effects resulted in a lower steady-state concentration of
oligomers in both cases, in spite of the accelerated overall
aggregation process in the case of Aβ4228. Moreover, this molecule
was found to suppress the toxic effects of both αS and Aβ42
oligomers in cultured human neuroblastoma cells by markedly
reducing the affinity of these aggregates for the cell
membrane20,28. We also found that squalamine, an aminosterol
comparable in structure to trodusquemine but with one less
positive charge in its polyamine chain, similarly reduces the
toxicity of αS oligomers to cells by their displacement from cell
membranes22. Collectively, the studies on trodusquemine and
squalamine raise the hypothesis that the aminosterol family of
molecules can protect the cells from the deleterious interaction of
misfolded oligomeric species20,22,28. Furthermore, trodusquemine
exhibits an apparently enhanced potency over squalamine against
the aberrant behavior of αS, as manifested by its ability also to
inhibit more strongly the fibril amplification process, and to
reduce the toxicity toward human neuroblastoma cells at lower
concentrations. In addition, both aminosterols lower the toxicity
caused by αS aggregation in a worm model of Parkinson’s
disease20,22, and trodusquemine lessened the toxicity related
to Aβ42 aggregation in a worm model of Alzheimer’s disease28.
In the present work, we studied the general mechanism of
action of trodusquemine at the molecular level on a range of
oligomeric systems. In particular, we investigated oligomers of αS
and Aβ due to their roles in Parkinson’s and Alzheimer’s diseases,
respectively. We used oligomers of Aβ40 in a recently character-
ized form stabilized by zinc ions29, which are distinct from the
Aβ42 ADDLs described previously28. In addition, we also studied
oligomeric species produced from the N-terminal domain of the
HypF protein from E. coli (HypF-N)8,30 in order to explore the
effects of trodusquemine on another well-characterized model
of misfolded protein oligomers. We also explored the effects of
trodusquemine on the morphological and structural properties of
the oligomers thought to be responsible for mediating their
toxicity. Our results reveal that trodusquemine protects cultured
neuroblastoma cells from the toxicity induced by all the types of
oligomers that we studied through markedly attenuating their
interaction with cell membranes in the absence of any detectable
structural changes and supramolecular reorganization. On the
basis of these findings, we suggest that aminosterols and other
molecules that act in a similar manner may function through a
generic mechanism as therapeutic agents to combat a variety of
human protein misfolding disorders.
Results
Trodusquemine inhibits oligomer toxicity toward cells. Because
of the heterogeneous and transient nature of protein misfolded
oligomers, it is typically necessary to isolate and stabilize them
through physical or chemical means to study their physico-
chemical, structural and biological properties. For example, only a
maximum of 1% of the total monomer concentration for Aβ is
oligomeric at the half-point of the in vitro aggregation reaction
when carried out at the concentrations used in this work31,32.
A key advantage of the methodologies employed herein for the
production of αS, Aβ40, or HypF-N oligomers is that they are
highly reproducible and yield markedly more homogeneous and
stable populations in comparison to the dynamical, metastable,
and heterogeneous aggregates that are formed during an endo-
genous aggregation reaction8,29,33.
We began our cellular investigations by determining the ability
of toxic type A HypF-N oligomers8 (6 µM, monomer equiva-
lents), typically having a height of 2–6 nm, as determined with
atomic force microscopy (AFM)8, to reduce the viability of SH-
SY5Y cells. The solutions containing the oligomers and their
respective controls were incubated for 1 h at 37 °C in the absence
and presence of 10:1, 3:1, and 1:1 ratios of oligomers to
trodusquemine, and were subsequently added to the culture
medium of the cells for 24 h (Fig. 1a). In the presence of the
HypF-N oligomers alone, the ability of cells to reduce MTT was
decreased to 76 ± 3% of that of untreated cells, indicating a
significant decrease in viability (P= 0.001, one-way ANOVA
relative to untreated cells), in agreement with previous studies8.
The addition of trodusquemine, however, was observed to
improve significantly the viability of the cells, such that the
toxicity of the oligomers was nearly eliminated when incubated
with an equimolar concentration of the small molecule (P=
0.031, one-way ANOVA relative to cells treated with oligomers;
Fig. 1a). Indeed, the small decrease in cellular viability at the
highest concentration of trodusquemine used in this study (6 µM)
to 91 ± 4% of that of untreated cells was essentially identical to
that observed in cells treated with corresponding concentrations
of trodusquemine in the absence of oligomers, to 94 ± 2% of that
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of untreated cells (Fig. 1b). Cells were also incubated under the
same conditions with 2% triton X-100 as a positive control in the
MTT assay, and cell viability was quantified to be 8.0 ± 0.3% of
untreated cells after being lysed (Supplementary Fig. 1).
In a second set of experiments, we investigated the effects of
trodusquemine on zinc-stabilized Aβ40 oligomers29. Aβ40 oligo-
mers stabilized by zinc ions represent a valuable oligomeric model
for studying the acute toxicity associated with Alzheimer’s disease
because they are not stabilized by an invasive chemical-physical
modification, but rather by a metabolite that is naturally present
at synapses. This model may therefore resemble populations of
oligomers endogenously occurring in the brain29. While Aβ40 is
more abundant than Aβ42 (80–90% versus 5–10% of total Aβ in
the brain1,3,34,35), the more hydrophobic Aβ42 has been shown to
be more toxic and aggregation prone35,36, and we have previously
studied in detail the effects of trodusquemine on Aβ4228.
In these measurements, zinc-stabilized Aβ40 oligomers29
(5 µM, monomer equivalents), typically having a height of
1–5 nm as determined with AFM29, were pre-incubated in a
similar manner to those of HypF-N, again for 1 h at 37 °C in the
absence and presence of trodusquemine at ratios of the oligomers
to trodusquemine of 10:1, 3:1, and 1:1, and then added to the
culture medium of the cells for 24 h (Fig. 1c). In the presence of
Aβ40 oligomers, the ability of cells to reduce MTT was decreased
to 75 ± 3% of untreated cells, indicating a significant decrease in
viability (P= 0.003, one-way ANOVA relative to untreated cells).
As was observed in the case of HypF-N oligomers, the addition of
increasing concentrations of trodusquemine markedly improved
the viability of cells in a dose-dependent manner, and cells treated
with oligomers and an equimolar concentration of the molecule
had a viability of 97 ± 4% of untreated cells (P= 0.010, one-way
ANOVA relative to cells treated with oligomers) (Fig. 1c), a value
that is essentially identical to that of cells treated with 6 µM
trodusquemine alone (Fig. 1b).
Previously, we reported that the viability of SH-SY5Y cells
measured by the MTT test in the presence of toxic, 4.3 ± 0.9 nm
in height as measured with AFM33, type B αS oligomers (0.3 µM,
monomer equivalents) was reduced to 79 ± 2% in the absence of
trodusquemine, and increased with a well-defined dose depen-
dence to 99 ± 2% upon the addition of an equimolar concentra-
tion of trodusquemine20. Of note, it has previously been
demonstrated that these concentrations of trodusquemine do
not displace monomeric αS from membranes20, suggesting that
physiologically relevant concentrations of the molecule would not
impact the normal association of monomeric αS with cell
membranes. Collectively, therefore, cell viability was recovered
to 91 ± 4%, 97 ± 4%, and 99 ± 2% of untreated cells in the
presence of a 1:1 ratio of trodusquemine to oligomers for HypF-
N, Aβ40 and αS oligomers, respectively, suggesting that the degree
of protection of the cells is independent of the oligomer type.
The oligomer concentrations administered to cells of 6 µM, 5 µM,
and 0.3 µM for HypF-N, zinc-stabilized Aβ40, and αS oligomers,
respectively, were selected based on preliminary observations that
oligomer toxicity peaks at these concentrations. To illustrate this
point, we incubated human neuroblastoma cells with 0, 1, 6, 12, 24,
and 48 µM concentrations of HypF-N oligomers, 0, 0.5, 1, 2.5, 5, 10,
20, 30, and 40 µM concentrations of zinc-stabilized Aβ40 oligomers,
and 0, 0.03, 0.3, and 3 µM concentrations of αS oligomers
(Supplementary Fig. 2). For these three systems, we found that
the toxicity correlated non-linearly with the oligomer concentration,
given that at high concentrations oligomers coalescence into larger,
less toxic aggregates. Also in consideration of the observation
that trodusquemine is soluble and monomeric at a concentration
of 10 µM in phosphate-buffered saline solution20, we elected to
use the aforementioned concentrations of oligomers in cells and
in vitro.
Oligomer displacement from membranes by a generic
mechanism. The affinity of misfolded protein oligomers for cell
membranes has been shown to correlate closely with the extent of
their ability to induce cellular toxicity37,38. In the light of this
connection, and of previous findings indicating that trodusque-
mine can displace αS and Aβ42 oligomers from membranes20,28,
we performed experiments using confocal microscopy to probe
the interactions between the stable oligomers of HypF-N and
Aβ40 with the membranes of SH-SY5Y neuroblastoma cells to
determine if the mechanism of action of trodusquemine is generic
to multiple types of oligomers. The cells were treated for 15 min
at 37 °C with HypF-N oligomers (6 µM, monomer equivalents) or
Aβ40 oligomers (5 µM, monomer equivalents) in the absence and
presence of 10:1, 3:1, and 1:1 ratios of oligomers to trodusque-
mine. The binding of oligomers to the membranes was monitored
using anti-HypF-N or 6E10 sequence specific anti-Aβ antibodies
(green channel) and wheat germ agglutinin (red channel)
to label the oligomers and membranes, respectively, as previously
Fig. 1 Trodusquemine reduces the toxicity of HypF-N and Aβ40 oligomers toward human neuroblastoma cells. a Oligomers of HypF-N (6 µM, monomer
equivalents) were resuspended in the cell culture medium in the absence (black) and presence of 10:1, 3:1, and 1:1 (light to dark red) molar ratios of
oligomers to trodusquemine (TRO), incubated for 1 h at 37 °C, and subsequently added to the cell culture medium of SH-SY5Y cells for 24 h. Untreated
cells exposed only to cell culture medium are shown for reference (blue). b Cells were also treated with the corresponding concentrations of
trodusquemine (0.6, 2, and 6 µM; gray bars) pre-incubated in the absence of oligomers under the same conditions. c Aβ40 oligomers stabilized by Zn2+
(5 µM, monomer equivalents) were incubated and administered to cells under the conditions described in a. Comparisons were carried out by one-way
ANOVA relative to untreated cells (indicated by the P values in blue text) and cells treated with oligomers alone (indicated by the P values in black text).
All bars indicate mean ± standard error of the mean (s.e.m.) of n= 3 biologically independent experiments (dots).
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described22. Cells were monitored at apical planes to avoid
visualizing oligomers that may have internalized into the cytosol.
Extensive oligomer binding to the apical planes of the cells was
observed in the absence of trodusquemine for both HypF-N
and Aβ40 oligomers, while in the presence of increasing
concentrations of trodusquemine, the binding was decreased with
a well-defined dose dependence (Figs. 2 and 3), as shown from
measurements of the degree of colocalization between oligomers
and membrane surfaces (Figs. 2 and 3). Indeed, at equimolar
concentrations of trodusquemine and oligomers, oligomer binding
was reduced by 65 ± 2% for HypF-N, 65 ± 4% for Aβ40 and 71 ±
2% for αS, the latter data being taken from a previous
publication20. As observed for the reduction in oligomer toxicity,
the degree of displacement is very similar across the proteins
Fig. 2 Trodusquemine reduces the membrane binding affinity of HypF-N oligomers to cultured human neuroblastoma cells. Representative confocal
scanning microscopy images of the apical sections of SH-SY5Y cells treated for 15 min at 37 °C with HypF-N oligomers (6 µM) in the absence (black) or
presence of 10:1, 3:1, and 1:1 ratios of HypF-N to trodusquemine (light to dark red). Red and green fluorescence indicates the cell membranes and the
oligomers, respectively. The percentage of colocalization between membranes and HypF-N oligomers are shown. In all, 50–60 cells were analyzed per
condition. Bars indicate the mean ± s.e.m. of n= 3 biologically independent experiments (dots). Statistical analyses were carried out by one-way ANOVA
relative to cells treated with oligomers in the absence of trodusquemine. Scale bars, 10 µm.
Fig. 3 Trodusquemine reduces the membrane binding affinity of Aβ40 oligomers to cultured human neuroblastoma cells. Representative confocal
scanning microscopy images of the apical sections of SH-SY5Y cells treated for 15 min at 37 °C with Aβ40 oligomers (5 µM) in the absence (black) and
presence of 10:1, 3:1, and 1:1 ratios of Aβ40 to trodusquemine (light to dark red). Red and green fluorescence indicates the cell membranes and the
oligomers, respectively. The percentage of colocalization between membranes and Aβ40 oligomers are shown. In all, 50–60 cells were analyzed per
condition. Bars indicate the mean ± s.e.m. of n= 3 biologically independent experiments (dots). Statistical analyses were carried out by one-way ANOVA
relative to cells treated with oligomers in the absence of trodusquemine. Scale bars, 10 µm.
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-01140-8
4 COMMUNICATIONS BIOLOGY |           (2020) 3:435 | https://doi.org/10.1038/s42003-020-01140-8 | www.nature.com/commsbio
investigated here, suggesting that the protection of the cell
membranes by trodusquemine is dominated by the displacement
of the cytotoxic oligomers from the surface of the membrane.
Recent studies have demonstrated that the uptake of
intrinsically disorder proteins, including Aβ, is a key step in its
mechanism of toxicity39–41. It is therefore possible that the
trodusquemine-induced displacement of oligomers from cell
membranes could also suppress protein uptake and its associated
toxicity, as the binding of the oligomers to the membrane is a
necessary step for their internalization. Indeed, we observed
minimal oligomer internalization in the presence of trodusque-
mine, when the cells were analyzed at median planes to focus on
their interior (Supplementary Figs. 3 and 4).
To investigate further the mechanism by which the cell
membrane is protected from oligomeric aggregates by trodus-
quemine, we next formed small unilamellar vesicles comprised
of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), dio-
leoyl-sn-glycero-3-phospho-L-serine (DOPS) and 1,2-dioleoyl-
sn-glycero-3-phosphocholine (DOPC) at a ratio of 5:3:2, which
represents a physiologically relevant model membrane system42–44.
Increasing concentrations of trodusquemine (ranging from 0–20
µM) were added to the vesicles at a total phospholipid
concentration of 100 µM, and their size was monitored using
static and dynamic light scattering (Supplementary Fig. 5).
Both light scattering measurements clearly indicate that vesicle
size increases with trodusquemine concentration. Indeed, the
diameter was increased from ~22 nm to over 100 nm in the
presence of a 5 µM concentration of trodusquemine. Based on
these results, we hypothesize that the affinity of the oligomers for
membranes may decrease in part as a consequence of the
increasing stiffness of the membranes as the concentration of
trodusquemine is increased.
Trodusquemine exerts minimal effects on oligomer structures.
In order to understand if trodusquemine exerts a protective effect
by mechanisms other than displacement from cell membranes,
we investigated whether or not the molecule has the ability to
affect the structural properties of the different types of oligomers
examined in this study up to the 1:1 molar ratio at which a full
suppression of oligomer toxicity is observed.
A large body of literature has shown that the physicochemical
properties of misfolded oligomers, in particular size and hydro-
phobicity, can be linked to their biological activity3,8,45–47.
We therefore first sought to measure the solvent exposure of the
oligomeric aggregates incubated in the presence of trodusquemine.
15 µM 8-anilinonaphthalene-1-sulfonate (ANS) was added to
solutions containing the oligomers of αS, Aβ40, and HypF-N after
their pre-incubation at a concentration of 5 µM in 20mM
Tris, 100mM NaCl, pH 7.4, in the absence and presence of 10:1,
3:1, and 1:1 ratios of oligomers to trodusquemine (1 h at 20 °C).
The binding of ANS to the oligomers of all three proteins in the
absence of trodusquemine was observed to increase the fluores-
cence intensity of the dye and to shift the wavelength of maximum
fluorescence to lower wavelengths (Fig. 4a), in agreement with
previous observations8,45,46. Incubation of the oligomers with
trodusquemine was found to increase slightly the maximum
fluorescence intensity (Fig. 4a). The wavelength of maximum
ANS fluorescence (λmax) was largely unchanged with increasing
concentrations of trodusquemine (Fig. 4b). Taken together,
the analyses indicate that trodusquemine is not appreciably
altering the hydrophobicity of the oligomers at the concentrations
used in the cell studies. As a control, the fluorescence intensity and
λmax value of free ANS remained unchanged at the highest
concentration of trodusquemine (i.e. 5 µM) in the absence of
oligomers (Fig. 4a).
We next sought to determine the impact of trodusquemine on
the size of the oligomeric aggregates. The same samples as those
used in the ANS binding experiments were examined, and
incubation of the various oligomers with trodusquemine was not
found to generate an observable increase in turbidity, as shown in
the experimental traces (Fig. 4c) and quantified at 350 nm48, at 10:1,
3:1, and 1:1 ratios of oligomers to trodusquemine (Fig. 4d). Samples
were also prepared under the same conditions in the absence of
ANS and measured using static light scattering. Data are shown as
the change in light scattering relative to oligomers in the absence of
the molecule. In agreement with the turbidity measurements, we
did not observe overt changes in the extent of light scattering upon
the incubation of oligomers with 10:1, 3:1, and 1:1 ratios of
oligomers to trodusquemine for any of the three systems (Fig. 4d).
The light scattering measured for 5 µM trodusquemine in the
absence of oligomers was below the detection threshold, further
indicating that the small molecule is not aggregating under these
conditions. In both of these measurements, the size of the oligomers
was not increased at the highest concentrations of trodusquemine
tested in cells (i.e. an equimolar concentration of trodusquemine,
Fig. 4c, d), as was also confirmed by dynamic light scattering for αS
oligomers (Supplementary Fig. 6) and high-resolution, phase
controlled AFM for Aβ40 oligomers (Supplementary Fig. 7),
suggesting that the decrease in oligomer cytotoxicity is predomi-
nantly driven by ability of trodusquemine to displace protein
misfolded oligomers from cell membranes, rather than by a change
in the oligomer structure induced by sub-stoichiometric to
equimolar concentrations of trodusquemine. These results are
furthermore consistent with our previous investigation on the
effects of trodusquemine on Aβ42 oligomers, wherein it was
observed that an equimolar concentration of the molecule did not
appreciably alter the size of the oligomers28. Indeed, all our results
indicate that displacement, rather than a change in oligomer size or
hydrophobicity, is the driving force behind the suppression of
oligomer toxicity in cells.
We then sought to characterize the secondary structure of the
different types of oligomers in the absence and presence of
trodusquemine by means of Fourier transform infrared spectro-
scopy (FTIR). We elected to use FTIR, as opposed to circular
dichroism, given its sensitivity to detect β-sheets present in
aggregated proteins, whereas circular dichroism spectroscopy can
suffer from differential absorption flattening, with flattened and
distorted spectra if aggregates are present in the sample49.
Oligomers were prepared as above but at 2mgmL−1, a concentra-
tion of protein that is sufficient to resolve reproducible and
sufficiently intense absorbance from the oligomers, and incubated
in the absence or presence of a 10-fold molar excess of
trodusquemine (Fig. 5a–c). Normalized spectra were analyzed using
a secondary derivative analysis (Fig. 5d–f). Even being in such
excess with respect to the oligomers, the presence of trodusquemine
was found to exert a negligible effect on the secondary structure of
Aβ40 and HypF-N oligomers upon its interaction (Fig. 5g). This was
similarly observed at lower concentrations of trodusquemine,
wherein a 2.5-fold excess of the molecule also did not impact
noticeably the secondary structure for these aggregates (Supple-
mentary Fig. 8). It can therefore be inferred that trodusquemine
does not modify the secondary structure of Aβ40 and HypF-N
oligomers at an equimolar concentration of oligomers to
trodusquemine. The αS oligomers, however, exhibited an increase
in both antiparallel (+5%) and parallel (+5%) β-sheet structure
with a decrease in the α-helical and random coil (−12%) content in
the presence of trodusquemine (Fig. 5g). Collectively, however,
these results indicate that the difference in oligomer binding to the
membranes and the toxicity at and below one molar equivalent of
trodusquemine (Figs. 1–3) is not likely to be related to changes in
the secondary structure of the aggregates.
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Fig. 4 The concentrations of trodusquemine used in the cell experiments do not appreciably modify the biophysical properties of αS, Aβ40, and HypF-
N oligomers. a Oligomers of αS, Aβ40 and HypF-N were incubated at a concentration of 5 µM in the absence (black) and presence of 10:1, 3:1, and 1:1 ratios
of oligomers to trodusquemine (dark to light gray) and monitored for the binding of ANS. Free ANS (green) and ANS+ 5 µM trodusquemine (brown)
are shown for comparison. b The wavelength of maximum ANS fluorescence (λmax) for oligomers of αS (blue), Aβ40 (black), and HypF-N (red) in the
presence of increasing concentrations of trodusquemine. c Turbidity absorbance measurements for the conditions described in a. d Turbidity values from
c quantified at 350 nm (triangles, left y-axis). Change in static light scattering (kilocounts per second, kcps) after oligomer incubation in the presence of
increasing concentrations of trodusquemine for the conditions described in b (dots, right y-axis). Static light scattering data indicate the mean ± s.e.m. of
n= 3 technical replicates. In a–c, data indicate mean ± s.e.m. of n= 2 spectra. ANS and turbidity spectra are representative of three independent
experiments that yielded consistent results. In b, d, P > 0.999 except where indicated (one-way ANOVA relative to oligomers in the absence of



















Fig. 5 Structural characterization of the various types of oligomers with a 10-fold excess of trodusquemine. IR absorbance measurements of oligomers
of αS (a), Aβ40 (b), and HypF-N (c) incubated in the absence (black) or presence of a 10-fold excess of trodusquemine (blue). The spectra were acquired in
triplicate and averaged and the error bars indicate the s.e.m. of n= 3 replicates corresponding to independent protein depositions of the same sample. All
spectra were normalized to assign an arbitrary value of 1.0 AU to the maximum absorbance. Corresponding secondary derivative analysis of the averaged
spectra for αS (d), Aβ40 (e), and HypF-N (f), with key inflection points corresponding to antiparallel β-sheet (light blue), α-helix (red), and parallel β-sheet
(purple) indicated with vertical dashed lines. g FTIR-derived secondary structure composition of the oligomers. Spectra were analyzed using a 2nd order, 12
point Savitzky-Golay filter. The presence of a 10-fold excess of trodusquemine was observed to increase the β-sheet content and reduce the combined
α-helix and random coil content of αS oligomers, while the overall structural compositions of Aβ40 and HypF-N oligomers were largely unchanged by the
presence of the molecule.
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Discussion
There has been a considerable focus in recent years on the soluble
oligomers formed during protein aggregation, leading to the
development of methods to stabilize, isolate, and characterize
such species to probe the origins of their cellular toxicity and of
their ability to induce synaptic dysfunction4. Indeed, targeting the
most cytotoxic species associated with protein deposition remains
an attractive strategy to develop therapeutic molecules capable of
arresting the development and progression of many diseases,
including Alzheimer’s, Parkinson’s and Huntington’s diseases
and type 2 diabetes1–6. In the present study, we have probed in
molecular detail the mechanism by which an aminosterol, tro-
dusquemine, is capable of reducing the toxicity of oligomers of
αS, Aβ, and HypF-N to human neuroblastoma cells.
We have found that the characteristic toxicity of these oligo-
mers is markedly reduced when incubated in the presence of
trodusquemine at concentrations at and below molar equivalence;
these concentrations were able to attenuate substantially the
binding affinity of oligomers to neuroblastoma cell membranes.
Investigation of the effects of trodusquemine on the size of the
oligomers showed that at these concentrations the size is largely
unaltered relative to that in the absence of the molecule. The
solvent exposed hydrophobic surface was found to be only
slightly augmented at low concentrations of trodusquemine. Since
the exposure of hydrophobic moieties in the interior of the oli-
gomers has been shown previously to increase toxicity8,45–47, this
effect would be expected to increase slightly the toxicity, but
trodusquemine was found, by contrast, to protect the cells from
damage initiated by these oligomeric species. Moreover, the sec-
ondary structure content of the oligomers was found to be largely
maintained in the presence of even a 2.5-fold or 10-fold molar
excess of the molecule. The physicochemical changes observed
herein for trodusquemine are appreciably different from our
recent characterization of the binding of designed antibodies to
Zn2+-stabilized Aβ40 oligomers, in which we observed prominent
increases in oligomer size and hydrophobicity50.
We therefore conclude that the dominant mechanism by which
trodusquemine reduces the toxicity of misfolded protein oligomers
is a displacement of the oligomers from cellular membranes rather
than a change in the inherent size and hydrophobicity of the
oligomers. These findings are in agreement with our previous
investigations into the effects of trodusquemine on oligomers of
Aβ42, where we found that cells pre-treated with trodusquemine
prior to their exposure to oligomers experience a reduced level of
oligomer binding to the cell membranes and of toxicity28. They
are also in agreement with our past studies on the effects of the co-
incubation of squalamine and trodusquemine with oligomers of
αS20,22. Collectively with our previous studies20,22,28, these results
demonstrate that trodusquemine can have effects also on the
process of fibril formation by reducing the steady-state population
of oligomers. In addition, we cannot discount completely the
possibility that oligomer assembly into larger species, with reduced
membrane binding and diffusional mobility, could also play a role
in the in vivo mechanism of action of trodusquemine. Such a
mechanism has been observed previously for a range of oligomers
in the presence of a variety of molecular chaperones30,51–53 and
some small molecules54,55. Moreover, evidence suggests that more
subtle effects than overt physicochemical changes to oligomer
structure, such as those observed upon certain chemical changes
to fibrils or oligomers, may play a key role in the ability of
intrinsically disordered proteins to induce toxicity56–59. While we
have found no clear evidence of structural changes on preformed
oligomers induced by the small concentrations of trodusquemine
for the oligomers studied herein, as assessed by their size, surface
hydrophobicity and secondary structure, we cannot exclude subtle
conformational alterations.
Amphiphiles, such as aminosterols, have been suggested to be
capable of partitioning into the cell membrane as a result of the
presence of both charged and hydrophobic regions, where the
positively charged segment of the molecule interacts with nega-
tively charged phospholipids on the inner leaflet of the plasma
membrane and hence can potentially neutralize negative surface
charges on the internal part of the membrane60–63; indeed, such a
mechanism has previously been postulated to attenuate viral
replication63. The reduced affinity of the oligomers for cell
membranes may perhaps be attributed, therefore, to the binding
of trodusquemine reducing the anionic character of the
lipid membranes. It is also possible that trodusquemine interacts
with the membrane at regions important for oligomer binding,
such as those enriched in the ganglioside GM137,64. In particular,
the negatively charged sialic acid of GM1 has been found to play a
key role in mediating binding of the oligomers to the membrane
and therefore toxicity64 and trodusquemine may act by reducing
its charge.
Our results show that it is possible that the formation of toxic
oligomers during endogenous aggregation reactions may gen-
erally be targeted directly or indirectly by trodusquemine, as the
molecule can act both on the kinetics of oligomer formation
and on their ability to interact with cell membranes to protect the
cell from damage. These observations suggest that the protection
of cell membranes by molecules such as aminosterols represents a
potential route to combat the pathological effects associated with
aggregation in protein misfolding diseases.
Methods
Preparation of HypF-N oligomers. Type A toxic oligomers were prepared as
previously described8. Briefly, purified wild-type monomeric HypF-N was resus-
pended at 0.5 mg mL−1 in 12% (v v−1) TFE, 2 mM DTT, 50 mM acetate buffer, pH
5.5, and incubated at 25 °C for 4 h. The solution was centrifuged at 16,100 × g and
20 °C for 15 min. The supernatant was removed and residual solvent was evapo-
rated off by gently drying the pellet with nitrogen gas, followed by resuspension in
buffer (20 mM Tris, 100 mM NaCl, pH 7.4) or cell culture medium.
Preparation of Aβ40 oligomers. Toxic oligomers were prepared as previously
described using LoBind tubes (Eppendorf, Hamburg, Germany)29. Lyophilized
Aβ40 was dissolved in 300 µL hexafluoroisopropanol (HFIP) and incubated over-
night at 4 °C. The solvent was gently removed using a flow of nitrogen gas, and the
film containing the protein was resuspended in 100% DMSO at a concentration of
2.2 mM. Two sonication steps of 10 min in duration were performed, after which
the protein was diluted to give a final concentration of 100 µM in 20 mM sodium
phosphate buffer, 200 μM ZnCl2, pH 6.929. After 20 h, samples were centrifuged at
(15 min, 16,100 × g, 20 °C). The supernatant was removed and the pellet containing
the oligomers was resuspended to the desired peptide concentration in buffer
(20 mM Tris, 100 mM NaCl, pH 7.4) or cell culture medium.
Preparation of α-synuclein oligomers. Type B toxic oligomers of α-synuclein
were prepared as previously described33. Briefly, the protein was purified into
phosphate-buffered saline (PBS) and subsequently dialyzed against water (4 L;
overnight, 4 °C). In all, 6 mg aliquots were lyophilized for 2 days, followed by
resuspension in buffer (500 μL of 20 mM Tris, 100 mM NaCl, pH 7.4). The
resuspended protein was passed through 0.22 μm filters and incubated (20–24 h,
37 °C). The samples were ultracentrifuged (1 h, 90,000 rpm, 20 °C) in a TLA120.2
rotor using an Optima TLX Ultracentrifuge (both Beckman Coulter, High
Wycombe, UK) to remove aggregates and large oligomers. Any remaining
monomeric protein was removed using a 100-kDa centrifugation filter (4×; 2 min,
10,000 rpm). The flow through containing predominantly monomeric protein from
the first three passes was kept and reused up to five times. The oligomer con-
centration was determined by UV spectroscopy using an extinction coefficient of
5600M−1cm−1 at 275 nm.
Incubation of oligomers with trodusquemine. Trodusquemine was synthesized
as a hydrochloride salt at a purity >97% as previously described20,28 and lyophi-
lized. Aliquots at a concentration of 10 mM were prepared after dissolution in
water and stored at −20 °C until use. After oligomer formation, samples were
incubated in the absence or presence of trodusquemine as indicated in the text.
Dynamic light scattering was used to assess if micellar or colloidal aggregates of
trodusquemine were present at the highest concentration investigated in these
experiments (20 mM Tris, 100 mM NaCl, pH 7.4, 50 µM trodusquemine incubated
for 1 h at 20 °C). Tween 20 was measured at a concentration in excess of its critical
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micelle concentration as a positive control. These measurements suggest that
trodusquemine is predominantly monomeric under these conditions (Supple-
mentary Fig. 9), in agreement with our previous NMR studies20.
Neuroblastoma cell culture. Human SH-SY5Y neuroblastoma cells (A.T.C.C.,
VA, USA) were cultured in DMEM, F-12 HAM with 25 mM HEPES and NaHCO3
(1:1) and supplemented with 10% FBS, 1 mM glutamine, and 1.0% antibiotics. Cell
cultures were maintained in a 5% CO2 humidified atmosphere at 37 °C and grown
until they reached 80% confluence for a maximum of 20 passages37,64,65. The cell
lines were authenticated by the European Collection of Authenticated Cell Cultures
using short tandem repeat loci analyses and they tested negatively for mycoplasma
contaminations.
MTT reduction assay. Cell viability was measured by the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay28,37,65. Oligomers of
Aβ40 (5 µM, monomer equivalents) or HypF-N (6 µM, monomer equivalents) were
incubated with or without increasing concentrations of trodusquemine for 1 h at
37 °C under shaking conditions, and then added to the cell culture medium of SH-
SY5Y cells seeded in 96-well plates for 24 h. The molar ratios of oligomers to
trodusquemine used here (monomer equivalents) were 10:1, 3:1, and 1:1. Samples
were distributed throughout the mutliwell plate by random allocation. After 24 h,
the cells were incubated with 0.5 mg mL−1 MTT at 37 °C for 4 h, and with cell lysis
buffer (20% SDS, 50% N,N-dimethylformamide, and pH 4.7) for 3 h. The absor-
bance values of blue formazan that are produced upon mitochondrial reduction of
MTT were determined at 590 nm. Cell viability was expressed as the percentage of
MTT reduction in treated cells as compared to untreated cells.
Oligomer binding to the cell membrane. SH-SY5Y cells were seeded on glass
coverslips and treated for 15 min with HypF-N oligomers (6 µM) or Aβ40 oligo-
mers (5 µM) or in the absence or presence of increasing concentrations of tro-
dusquemine (10:1, 3:1, and 1:1 ratios of oligomers to trodusquemine, monomer
equivalents). After incubation, the cells were washed with PBS and counterstained
with 5.0 µg mL−1 Alexa Fluor 633-conjugated wheat germ agglutinin (Life Tech-
nologies, CA, USA)22,28. After washing with PBS, the presence of Aβ40 or HypF-N
oligomers was detected with 1:800 diluted mouse monoclonal 6E10 anti-Aβ anti-
bodies (BioLegend, CA, USA) or 1:800 diluted rabbit monoclonal anti-HypF-N
antibodies (Primm, Milan, Italy) and subsequently with 1:1000 diluted Alexa Fluor
488-conjugated anti-mouse or anti-rabbit secondary antibodies (Life Technologies,
CA, USA) to recognize the 6E10 and anti-HypF-N primary antibodies, respectively.
Fluorescence emission was detected after double excitation at 488 nm and 633 nm
by the scanning confocal microscopy system described previously22 and three
apical sections were projected as a single composite image by superimposition. The
percentages of oligomer colocalization were determined by analyzing regions of
interest corresponding to 50–60 cells per condition.
Model membrane measurements. All lipids were purchased from Avanti Polar
Lipids, Inc. (AL, USA). Lipid vesicles comprised of DOPE:DOPS:DOPC in a ratio
of 5:3:2 were prepared as previously described with sonication44 and at a final
concentration of 100 µM. Light scattering measurements were carried out as
described below.
ANS binding measurements. In all, 8-anilinonaphthalene-1-sulfonate (ANS,
Sigma-Aldrich, MO, USA) was added at a 3-fold excess with respect to oligomers
(15 µM ANS to 5 µM oligomers). The binding of ANS to oligomers generates a
protein-ANS complex with an increased quantum yield relative to unbound dye,
where increased solvent exposure of protein-ANS complex can be observed by a
blue-shift in the wavelength of maximum fluorescence and an increase in the
fluorescence intensity46. Emission spectra were recorded in a 96-well plate (product
number 3881, Corning, NY, USA) using a plate reader (BMG Labtech, Aylesbury,
UK) with excitation at 380 nm. Duplicate samples are shown and the data are
representative of three independent experiments using fresh oligomer preparations
that gave consistent results, and all traces were background subtracted against
buffer alone.
Turbidimetry measurements. Samples from the ANS preparation were analyzed
using a plate reader (BMG Labtech, Aylesbury, UK) with spectral scanning. Spectra
were acquired from 350 to 650 nm and quantified according to their absorbance at
350 nm48. Duplicate samples are shown and the data are representative of three
independent experiments using fresh oligomer preparations that gave consistent
results, and all traces were background subtracted against buffer alone.
Static light scattering. Static light scattering measurements were performed with
fixed parameters for attenuator, as determined at the beginning of each series of
measurements for the relevant oligomers alone sample, and cell position at 25 °C
using the Malvern Zetasizer Nano S instrument (Malvern, Worcestershire, UK)
equipped with a Peltier temperature controller. A low volume (70 µL) disposable
cuvette was used (BRAND, Wertheim, Germany). The data are shown as the
change in light scattering relative to oligomers in buffer.
Dynamic light scattering. Dynamic light scattering was performed using the
same materials and conditions described for static light scattering measure-
ments, but with automatic settings for the attenuator and position for each
sample. Measurements of trodusquemine alone were carried out at 37 °C and
attenuator 11.
Atomic force microscopy. Oligomers of Aβ40 were incubated at a concentration
of 5 µM in the absence or presence of 5 µM trodusquemine. The mica substrate
was positively functionalized by incubation with a 10-μL drop of 0.05% (v v−1)
APTES ((3-aminopropyl)triethoxysilane, Sigma-Aldrich, MO, USA) in Milli-Q
water for 1 min at ambient temperature, rinsed with Milli-Q water and then
dried with a gentle flow of gaseous nitrogen66. AFM sample preparation was
performed at room temperature by deposition of a 10-µL drop for 2 min onto the
treated mica substrate. Salts were washed with water, the samples were dried by
the gentle flow of nitrogen, and stored in a sealed container until imaging using a
JPK Nanowizard2 AFM instrument (JPK Instruments, Berlin, Germany) with
scan rates < 0.5 Hz and a silicon tip with a 10 nm nominal radius (2 N m−1).
Three-dimensional maps were flattened using SPIP software (Image Metrology,
Hørsholm, Denmark).
Fourier transform infrared spectroscopy. Oligomeric samples were prepared at a
concentration of 2 mgmL−1 in buffer (corresponding to monomer equivalents of
0.14 mM, 0.46 mM, and 0.18 mM for αS, Aβ40, and HypF-N oligomers, respec-
tively) and incubated as above in the absence or presence of a 2.5- or 10-fold molar
excess of trodusquemine. ATR-FTIR spectroscopy was performed using a Bruker
Vertex 70 spectrometer equipped with a diamond ATR element (Bruker, MA,
USA). Spectra were recorded with a resolution of 4 cm−1. Each sample was ana-
lyzed in triplicate and the spectra were averaged over 512 scans. After drying the
samples by evaporation, they were washed with Milli-Q water to remove unbound
trodusquemine (i.e. to minimize absorbance in the region beyond the Amide II
band, see Supplementary Fig. 10 for the FTIR spectrum of trodusquemine alone)
and allowed to dry prior to data collection.
Statistics and reproducibility. Data were analyzed in GraphPad Prism 8.4 (CA,
USA) by one-way ANOVA followed by Bonferroni’s post comparison test except
where otherwise indicated, and P < 0.05 was accepted as statistically sig-
nificant28. The N values, P values, number of technical replicates, and number of
independent experiments performed for each type of measurement are listed
where applicable.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data generated or analyzed in this study are included in the article and supporting
information. Data for the main figures are provided as Supplementary Data 1, and all
data are available from the authors upon reasonable request.
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